The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. This approval follows the Phase 3 EMBER-3 trial, where the combination doubled median progression-free survival to 11.1 months compared to 5.5 months with Inluriyo alone. The all-oral regimen targets two key drivers of tumor growth with manageable side effects and no new monitoring requirements. This treatment offers a significant new option for patients with resistant ER+ breast cancer and is now available in the U.S.
Following the FDA approval of Eli Lilly's Inluriyo combined with Verzenio, Eli Lilly's stock (LLY) trades at USD 1,148.05 on Pluang as of Sep 19, 2026 01:04 WIB, showing a slight 0.35% decline in one day. The stock holds a market cap of $1.03 trillion and has a dividend yield of 0.6%, with typical investor hold time around 92 days. Current Pluang order activity leans more towards selling at 63%.
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven mainly by volume growth from key drugs like Mounjaro and Zepbound, with earnings per share beating estimates. Despite a bullish pipeline and raised revenue guidance, the company faces cha...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with...
The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benc...
Eli Lilly's stock fell 8.44% in the past month despite strong business growth, driven by concerns over pricing and acquisition charges. The company leads the obesity and diabetes market with blockbuster drugs Mounjaro and Zepbound, generating $14.9 b...
